LIVALO

This brand name is authorized in United States. It is also authorized in Brazil, Japan, Singapore.

Active ingredients

The drug LIVALO contains one active pharmaceutical ingredient (API):

1	Pitavastatin UNII IYD54XEG3W - PITAVASTATIN CALCIUM
	Pitavastatin competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in the biosynthesis of cholesterol, and inhibits cholesterol synthesis in the liver.
	Read more about Pitavastatin

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
LIVALO Film-coated tablet	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
C10AA08	Pitavastatin	C Cardiovascular system → C10 Lipid modifying agents → C10A Lipid modifying agents, plain → C10AA HMG CoA reductase inhibitors
Discover more medicines within C10AA08

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
BR	Câmara de Regulação do Mercado de Medicamentos	507612110017502, 507612110017602, 507612110017802
JP	医薬品医療機器総合機構	2189016F1028, 2189016F2024, 2189016F3020, 2189016F4027, 2189016F5023, 2189016F6020
SG	Health Sciences Authority	15859P, 15860P
US	FDA, National Drug Code	66869-104, 66869-204, 66869-404